The HDAP HIV Drug Resistance Assay Reimbursement program provides direct reimbursement to healthcare sites for the cost of genotype and virtual phenotype testing for their uninsured HIV-positive patients.

Drug resistance testing is an important tool to measure whether a person’s virus is resistant to antiviral medications. With the help of genotype and phenotype testing, physicians can make an informed and individualized decision about the most effective antiretroviral therapies for each of their patients.

For more information or to enroll in the HIV Drug Resistance Assay Reimbursement program, interested healthcare sites should contact Craig Wells, Deputy Executive Director/IDDAP Program Director, at 617.502.1734 or, or call CRI’s main number at 617.502.1700.